Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AUR112 · 1 trial · 1 indication
Number of participants with dose limiting toxicities (DLT) taking AUR112
The assessment of safety was based on the frequency of deaths, adverse event (AE), serious adverse event (SAE)s leading to discontinuation of study drug, and abnormalities in specific laboratory assessments. AEs and laboratory values will be graded for severity according to NCI CTCAE version 5.0
Determine selected dose(s) to be studied in future clinical trials
Maximum concentration of AUR112
Tmax in hours
Area under the curve (AUC) of AUR 112 in h\* mcg/mL
Average time the drugs stays in the body
Terminal elimination half-life of AUR 112 in hours
Compare in fast and fed conditions
Compare Tmax in fast and fed conditions
Compare AUC in fast and fed conditions
| Arm | Type | Description |
|---|---|---|
| AUR112 | EXPERIMENTAL | Experimental: AUR112, 100mg to 1200mg Currently, six (6) planned dose levels are 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, and 1200 mg once daily (QD). AUR112: Once daily |
| Name | Type | Description |
|---|---|---|
| AUR112 | DRUG | Once daily |
Inclusion Criteria: 1. Males and females ≥ 18 years of age 2. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1 3. Acceptable bone marrow and organ function at screening as described below: 1. ANC ≥ 1000/μL (without WBC growth factor support) 2. Platelet count: For patie...
AUR112 is an investigational small molecule being developed for the treatment of relapsed advanced lymphomas. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with relapsed advanced lymphomas to evaluate its safety, pharmacokinetics, and pharmacodynamics.
AUR112 targets MALT1, a protein involved in signaling pathways that can contribute to lymphoma development. By targeting MALT1, AUR112 aims to interfere with the survival and proliferation of lymphoma cells. This mechanism is being investigated in a Phase 1 clinical trial for patients with relapsed advanced lymphomas.
AUR112 is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting a Phase 1 clinical trial to evaluate the safety and other characteristics of AUR112 in patients with relapsed advanced lymphomas.
AUR112 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 1 trial is recruiting patients with relapsed advanced lymphomas to assess the drug's safety, pharmacokinetics, and pharmacodynamics.
AUR112 is being studied in a Phase 1 clinical trial with the identifier NCT06755450. The trial is titled 'Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma' and is currently recruiting participants in India. The study aims to enroll 40 patients aged 18 years and older.
AUR112 is a unique investigational drug and no alternative names have been reported. It is being developed by Dr. Reddy's Laboratories Ltd under the name AUR112. The drug is currently in Phase 1 clinical trials for the treatment of relapsed advanced lymphomas.